Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — J.P. Morgan Healthcare Conference 2026
22 slides from Xvivo Perfusion Ab's conference presentation, Jan 14, 2026
Slide 1: Extending horizons in organ transplantation
Extending horizons in organ transplantation Christoffer Rosenblad, CEO JPM January 14, 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT: THE INFORMATION CONTAINED IN THIS PRESENTATION IS PRIVATE AND CONFIDENTIAL, HAS BEEN FURNISHED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REFERRED TO, QUOTED, REPRODUCED, REDISTRIBUTED OR DISCLOSED IN ANY WAY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY OTHER PER
Slide 3: Today’s presenter
Today’s presenter Christoffer Rosenblad CEO DOC ID: XVIVO_JPM_2026
Slide 4: Nobody should die waiting for a new organ.
Alex Moroianu Heart recipient Australia Nobody should die waiting for a new organ. Far too many patients do not receive the help they need in time due to the acute shortage of transplantable organs. At XVIVO, we’re determined to change this.
Slide 5: We believe in an extended life of organs
We believe in an extended life of organs Nobody should die waiting for a new organ Pre-Transplant (In vivo) During-Transplant (Ex vivo) Post-Transplant Organ Organ Organ Organ Immuno- Post- Diagnostics Donor Care Transplant matching recovery preservation assessment suppresants surgical care We offer
Slide 6: Global leading all organ company in a rapidly growing transplant market
Global leading all organ company in a rapidly growing transplant market Business areas Main markets Strong presence in leading transplant markets Americas EMEA APAC 60% Thoracic Abdominal Services 35% 5% Key Financials Net Sales R12 EBITDA R12 85M USD 19% Founded Employees The share is listed on CAG
Slide 7: The transplant market
The transplant market DOC ID: XVIVO_JPM_2026
Slide 8: The global need
The global need All organs With only 170,000 organ transplants Approximately, performed globally each 1.7 million year, this only covers organ transplants are required every year. ~10% of the total need1 1. Those [2021] data are based on the Global Observatory on Donation and Transplantation (GODT)
Slide 9: Organ utilization opportunity
Organ utilization opportunity Utilization rates - US averages (2024) Lung 20% Heart 27% Kidney 64% Liver 64% DOC ID: XVIVO_JPM_2026
Slide 10: Changing dynamics driving rapid market growth
Changing dynamics driving rapid market growth Donors recovered in the USA Transplants CAGR 2023-2025: 18 All organs Lung tx +9% +11% Thousands 16 14 Increasing the donor pool through new 12 donor groups (e.g. extended criteria) 10 Significant potential in increasing DCD 8 transplant rates 6 Transpla
Slide 11: Solving the problem
Solving the problem DOC ID: XVIVO_JPM_2026
Slide 12: From market leaders in lung preservation to a beyond product portfolio
From market leaders in lung preservation to a beyond product portfolio Lung Heart Kidney & Liver Service Born from lung Expanded to a full World’s first all organ company Expansion beyond transplantation – now thoracic portfolio with with the acquisition of market product to address with more than 2
Slide 13: XVIVO’s offering – Best in class
XVIVO’s offering – Best in class Products Services XVIVO Organ LIVER LUNG Recovery Service XVIVO Organ Perfusion Service XPS | STEEN Solution | PERFADEX® Plus Liver Assist HEART KIDNEY XVIVO Insights XVIVO FlowHawk XVIVO Heart Assist Transport * | XVIVO Heart Solution | XVIVO Heart Solution Suppleme
Slide 14: Regulatory approval status in core markets
Regulatory approval status in core markets PMA approval for STEEN Solution STEEN Solution, XPS & STEEN Solution, XPS & & XPS / PERFADEX 510(k) cleared PERFADEX CE marked PERFADEX approved by the TGA Kidney Assist Transport Kidney Assist Transport Kidney Assist Transport 510(k) cleared CE marked appr
Slide 15: XVIVO is reshaping the industry
XVIVO is reshaping the industry Making more organs available for transplant Improving the lives for patients through better outcomes Reducing costs in the transplant system by improving efficiency Reshaping how transplants are performed – making procedures plannable DOC ID: XVIVO_JPM_2026
Slide 16: XVIVO is unique in the market
XVIVO is unique in the market Our competitive advantage Driving the market forward Bringing true innovation to market Optimising preservation through Research Extensive body of clinical evidence across all Perfusate Only company to have brought new and HOPE Hypothermic oxygenated perfusion major org
Slide 17: Outlook
Outlook DOC ID: XVIVO_JPM_2026
Slide 18: XVIVO is changing the world
XVIVO is changing the world Short-term focus USA: • Drive EVLP adoption in the US by leveraging perfusion service models • Establish standardized NRP procurement as a core XVIVO service offering in the US • Submission of the regulatory file to the FDA for XVIVO Heart Assist Transport including prese
Slide 19: Changing the paradigm of heart preservation
Changing the paradigm of heart preservation XVIVO heart technology makes first cross Atlantic heart transplant possible: Unprecedented distance covered: 6750km or 3659nm Extended preservation time: 12h06m out-of-body Commercial air transport Economy seat DOC ID: XVIVO_JPM_2026
Slide 20: XVIVO as an investment
XVIVO as an investment High growth potential, contributing to saving more lives in a rapidly changing market Market potential for XVIVO’s offer increases 1 machine perfusion is 10x larger than current 2 the availability of transplantable organs standard of care Future secured product History of cont
Slide 21: Nobody should die waiting for a new organ.
Nobody should die waiting for a new organ.
Slide 22: XVIVO Perfusion AB contact details
XVIVO Perfusion AB | Entreprenörsstråket 10 | SE-431 53 Mölndal | Sweden Tel +46 31 788 21 50 | xvivogroup.com XVIVO trademarks, names and logos are registered trademarks of XVIVO Perfusion AB. © 2023 2026 XVIVO Perfusion AB. All rights reserved.
XVIVO Perfusion — J.P. Morgan Healthcare Conference 2026 on 6ix